

Interim report of
MEDICLIN Aktiengesellschaft
for the period from 1 January 2025 to 31 March 2025

MEDICLIN: Key data on business development

	3M 2025	3M 2024
Number of shares in millions	47.5	47.5
Number of cases (inpatient)	26,064	26,703
Number of beds as of 31.03.	8,179	8,107
Occupancy rate in %	85.0	85.0
Number of full-time employees (average number)	6,912	6,984

In thousands of €	3M 2025	3M 2024
Cash flow from operating activities	17,087	17,141
Cash flow from operating activities per share in €	0.36	0.36
Sales	184,844	185,447
EBITDA	18,085	16,189
EBITDA margin in %	9.8	8.7
EBIT (operating result)	5,226	4,092
EBIT margin in %	2.8	2.2
Financial result	-5,218	-5,305
Total consolidated result	-97	-1,437
Earnings per share in €	0.00	-0.03
Gross capital expenditure	11,980	10,272
Thereof subsidies	2,092	2,387
Interest coverage factor (EBITDA / interest result)	3.5x	3.1x

In thousands of €	31.03.2025	31.12.2024
Balance sheet total	897,169	905,906
Equity	223,809	222,738
Equity ratio in %	24.9	24.6
Return on equity ¹ in %	11.7	11.2
Financial liabilities (to banks)	66,075	66,960
Cash and cash equivalents	105,030	107,563
Net financial debt ²	-13,037	-9,054
Net financial debt ² / EBITDA ³	-0.2x	-0.1x

¹ Total consolidated result in the last 12 months / equity

² Adjusted average net financial debt in the last four quarters

³ Adjusted EBITDA in the last 12 months

Due to arithmetical reasons, calculation differences of +/- one unit (€, % etc.) may occur; percentage rates and changes in % were calculated on the basis of non-rounded € values.

Report on the economic position for the first quarter of 2025

General statement on results of operations, financial position and net assets

Sales development in the Group and in the segments

In the first quarter of 2025, MEDICLIN generated Group sales of EUR 184.8 mill. Sales thus declined by EUR 0.6 mill. or 0.3 % year-on-year in the first three months of the current financial year. The stable sales development is attributable to a lastingly satisfactory occupancy rate of 85.0 %.

Significant year-on-year increase in total consolidated result

On the costs side, the cost of raw materials and consumables used was EUR 32.5 mill., corresponding to a decrease of EUR 3.0 mill. or 8.5 % compared to the prior-year value, while the cost of purchased services increased (EUR +3.0 mill. or 2.0 %). The further rise in energy costs had a particularly strong impact here (EUR +0.2 mill.). The sale of the former MEDICLIN Herzzentrum Coswig took the cost of raw materials and supplies down considerably by EUR 3.3 mill. or 15.3 %, respectively. The decrease in expenses was particularly noticeable with regard to implants (EUR –1.7 mill.) and medical supplies (EUR –1.3 mill.). Staff costs rose by EUR 3.5 mill. or 2.9 %, respectively. The increase was caused by the usual salary rises. The Group operating result improved by EUR 1.1 mill. to EUR 5.2 mill. (3M 2024: EUR 4.1 mill.). The figures in the quarter under review do not contain any energy cost allowances, whereas the prior quarter had included EUR 2.0 mill. in such allowances.

Gross capital expenditure amounted to EUR 12.0 mill. in the first quarter of 2025 (3M 2024: EUR 10.2 mill.). Cash and cash equivalents came to EUR 105.0 mill. on 31 March 2025 (31.12.2024: EUR 107.6 mill.). This item contains a total of about EUR 15.5 mill. in expected repayments to be made for benefits received under the protective shield to manage the COVID-19 pandemic. Furthermore, the cash and cash equivalents item includes approximately EUR 18.3 mill. in subsidies for the construction of a new clinic.

MEDICLIN intends to build on its strengths

MEDICLIN possesses strong expertise in rehabilitation and excels in seamless interdisciplinary collaboration between acute and post-acute care. These strengths enable MEDICLIN to offer comprehensive and patient-centred care solutions. The hospital reform (KHVVVG), which came into effect on 1 January 2025, is expected to bring changes, the full impact of which remains unclear. The acute care sector is expected to see a reduction in hospital beds and the development of outpatient structures, which could lead to a concentration of healthcare services in specialized centres. Although rehabilitation services are not explicitly considered in the Hospital Care Improvement Act (KHVVVG), MEDICLIN sees opportunities to further expand its leading role. A growing demand for therapeutic and preventive services is anticipated in order to close gaps in care supply. MEDICLIN intends to intensify its cooperation with hospitals and outpatient care providers and has developed innovative concepts to adapt to the changing requirements and to further optimise patient care.

Outlook

Sales and the Group operating result are within the normal range for the first quarter. The Management Board is thus optimistic that the forecast published in the 2024 Annual Report of sales growth in the range of 2.0 % to 5.0 % and Group EBIT between EUR 53.0 and 64.0 mill. will be reached in the 2025 financial year.

Results of operation, financial position and net assets

Results of operation

SALES AND EARNINGS PERFORMANCE OF THE GROUP

	3M 2025	3M 2024
Group sales in millions of €	184.8	185.4
Raw materials and consumables used in millions of €	32.5	35.6
Cost of materials ratio in %	17.6	19.2
Staff costs in millions of €	125.4	121.9
Staff costs ratio in %	67.9	65.7
Depreciation and amortisation in millions of €	12.9	12.1
Other operating expenses in millions of €	16.3	18.1
Group operating result in millions of €	5.2	4.1

Group sales in the first quarter of the 2025 financial year were EUR 0.6 mill. below the previous year's value, corresponding to a 0.3 % decrease. While the cost of raw materials and consumables used dropped by EUR 3.0 mill. or 8.5 %, the cost of purchased services rose (EUR +0.3 mill. or 2.0 %). The further rise in energy costs had a particularly strong impact here (EUR +0.2 mill.). The cost of raw materials and supplies, in turn, was reduced considerably by EUR 3.3 mill. or 15.3 %, respectively. The decrease in expenses was particularly noticeable with regard to implants (EUR –1.7 mill.) and medical supplies (EUR –1.3 mill.). The decline in the cost of raw materials and supplies was caused primarily by the sale of the former MEDICLIN Herzzentrum Coswig in 2024. Staff costs rose by EUR 3.5 mill. (+2.9 %).

Depreciation and amortisation increased by EUR 0.8 mill. or 6.3 % to EUR 12.9 mill (3M 2024: EUR 12.1 mill.).

The Group operating result improved significantly by EUR 1.1 mill. to EUR 5.2 mill.

The financial result of EUR –5.2 mill. was EUR 0.1 mill. above the previous year's level (3M 2024: EUR –5.3 mill.).

The total consolidated result attributable to shareholders of MEDICLIN Aktiengesellschaft was EUR –0.2 mill. (3M 2024: EUR –1.4 mill.). Earnings per share came to EUR 0.00, up from EUR –0.03 in the previous year.

The sales and earnings performance at segment level is shown in the segment reporting section.

Financial position and net assets

Cash and cash equivalents stood at EUR 105.0 mill. as at 31 March 2025 and were thus EUR 13.1 mill. below the prior-year level (31.03.2024: EUR 118.1 mill.). This item contains approximately EUR 15.5 mill. in expected repayments to be made for benefits received under the protective shield to manage the COVID-19 pandemic. Furthermore, the cash and cash equivalents item includes EUR 18.3 mill. in subsidies for the construction of a new clinic.

LIQUIDITY

In millions of €	3M 2025	3M 2024
Cash flow from operating activities	17.1	17.1
Thereof total consolidated result	−0.1	−1.4
Cash flow from investing activities	−7.3	−2.4
Cash flow from financing activities	−12.3	−11.9
Cash flow for the period	−2.5	2.8
Cash and cash equivalents at the beginning of the period	107.5	115.3
Cash and cash equivalents at the end of the period	105.0	118.1

There was no significant change in net assets as of the reporting date on 31 March 2025 compared to 31 December 2024.

BALANCE SHEET STRUCTURE

In millions of €	31.03.2025	In % of balance sheet total	31.12.2024	In % of balance sheet total
Assets				
Non-current assets	600.3	66.9	608.3	67.1
Current assets	296.9	33.1	297.6	32.9
	897.2	100.0	905.9	100.0
Equity and liabilities				
Equity	223.8	24.9	222.7	24.6
Non-current liabilities	509.2	56.8	517.2	57.1
Current liabilities	164.2	18.3	166.0	18.3
	897.2	100.0	905.9	100.0

Segment reporting

The sales development in the post-acute, nursing care and service segments was positive, while sales in the acute segment went down. This is mainly due to the sale of the former MEDICLIN Herzzentrum Coswig. Sales in the post-acute segment rose by 8.1 % to EUR 121.8 mill. (3M 2024: EUR 112.7 mill.), while sales in the acute segment went down by 15.7 % to EUR 55.3 mill. (3M 2024: EUR 65.7 mill.). The nursing care segment achieved 6.7 % growth to EUR 6.2 mill., up from EUR 5.9 mill. in the prior-year quarter. Sales in the service segment rose by 5.1 % to EUR 26.1 mill. The post-acute segment saw a decline in earnings by 16.6 % or EUR 1.0 mill. to EUR 4.9 mill. The result in the acute segment amounted to EUR 0.0 EUR, up from EUR –1.3 mill. in the previous year's quarter, corresponding to an increase by EUR 1.3 mill. The result in the nursing care segment was EUR –0.1 mill. and thus more or less on a par with the prior-year quarter (3M 2024: EUR 0.0 mill.). The result in the service segment amounted to EUR 0.4 EUR, up from EUR –0.5 mill. in the previous year's quarter, corresponding to an increase by EUR 0.9 mill.

SALES

In millions of €	3M 2025	3M 2024	Change in %
Post-acute	121.8	112.7	+8.1
Acute	55.3	65.7	-15.7
Nursing care	6.2	5.9	+6.7
Service	26.1	24.7	+5.1
Reconciliation	-24.6	-23.6	+4.5
Group	184.8	185.4	-0.3

RAW MATERIALS AND CONSUMABLES USED

	3M 2025	3M 2024	Change in %
Post-acute			
Raw materials and consumables used in millions of €	26.8	25.1	+6.6
Cost of materials ratio in %	22.0	22.3	
Acute			
Raw materials and consumables used in millions of €	15.7	19.6	-19.6
Cost of materials ratio in %	28.4	29.8	
Nursing care			
Raw materials and consumables used in millions of €	1.5	1.4	+5.8
Cost of materials ratio in %	23.5	23.7	
Service			
Raw materials and consumables used in millions of €	11.1	11.2	-0.3
Cost of materials ratio in %	42.7	45.1	

STAFF COSTS

	3M 2025	3M 2024	Change in %
Post-acute			
Staff costs in millions of €	69.1	61.7	+11.9
Staff costs ratio in %	56.7	54.8	
Acute			
Staff costs in millions of €	34.8	39.7	-12.4
Staff costs ratio in %	62.8	60.4	
Nursing care			
Staff costs in millions of €	3.4	3.0	+12.6
Staff costs ratio in %	54.9	52.1	
Service			
Staff costs in millions of €	18.4	17.7	+3.9
Staff costs ratio in %	70.7	71.5	

SEGMENT RESULT

In millions of €	3M 2025	3M 2024
Post-acute	4.9	5.9
Acute	0.0	-1.3
Nursing care	-0.1	0.0
Service	0.4	-0.5
Reconciliation	0.0	0.0
Group	5.2	4.1

Employees

The average number of employees, in terms of full-time employees, decreased in the first three months of 2025 compared to the prior-year period. The Group employed an average of 380 trainees in the first quarter of 2025 (3M 2024: 393 trainees).

AVERAGE NUMBER OF EMPLOYEES IN THE GROUP AND IN THE SEGMENTS

Shown in full-time employees	3M 2025	3M 2024	Change
Post-acute	3,742	3,520	+222
Acute	1,657	1,949	–292
Nursing care	211	207	+4
Service (including administration)	1,302	1,308	–6
Group	6,912	6,984	–72

Forward-looking statements

This report contains forward-looking statements that are based on management's current expectations. Words such as "anticipate", "assume", "believe", "estimate", "expect", "intend", "can/could", "may", "might", "plan", "project", "should" and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties that are based on the current assumptions and forecasts of MEDICLIN AG's management. Should any of these risks and uncertainties materialise, or if the assumptions underlying any of the forward-looking statements prove incorrect, then the actual results may be materially different from those expressed or implied by such statements. MEDICLIN AG does not intend or assume any obligation to continuously update these forward-looking statements, so as to adapt them to events or developments that occur after the release of this interim report.

Consolidated interim balance sheet as of 31 March 2025

ASSETS

in €	31.03.2025	31.12.2024
NON-CURRENT ASSETS		
Goodwill and other intangible assets		
Concessions, licences	5,999,860	6,552,881
Goodwill	16,395,079	16,395,079
Payments on account	2,164,971	1,766,688
	24,559,910	24,714,648
Property, plant and equipment		
Land, land rights and buildings including buildings on third-party land	101,084,058	102,535,418
Right-of-use assets on land, land rights and buildings incl. buildings on third-party land	337,872,445	344,985,376
Technical equipment and machines	9,615,331	9,696,047
Operating and office equipment	33,085,703	31,341,036
Right-of-use assets on operating and office equipment	2,278,864	2,562,318
Payments on account and assets under construction	46,532,954	42,178,051
	530,469,355	533,298,246
Financial assets		
Investment in stock of subsidiaries	58,822	58,822
Reinsurance cover	532,204	565,003
Other financial investments	2,056	2,056
	593,082	625,881
Other assets		
Receivables pursuant to hospital financing law	33,282,880	38,544,930
	33,282,880	38,544,930
Deferred tax assets	11,394,570	11,136,799
	600,299,797	608,320,504
CURRENT ASSETS		
Inventories	7,327,971	7,664,166
Trade receivables	89,089,043	99,569,383
Other financial assets		
Receivables pursuant to Hospital Compensation Act (KHEntgG) / Federal Directive on Nursing Care Rates (BPfIV)	61,606,849	57,227,660
Other current financial assets	8,871,249	7,906,214
	70,478,098	65,133,874
Other assets		
Prepaid expenses	5,211,975	2,724,758
Receivables pursuant to hospital financial law	19,655,450	14,853,458
	24,867,425	17,578,216
Cash and cash equivalents	105,030,342	107,563,091
Assets held for sale	76,702	76,702
	296,869,581	297,585,432
	897,169,378	905,905,936

EQUITY AND LIABILITIES

in €	31.03.2025	31.12.2024
EQUITY		
Share of MEDICLIN Group		
Subscribed capital	47,500,000	47,500,000
Capital reserve	129,391,829	129,391,829
Revenue reserve	38,299,890	37,142,113
Consolidated balance sheet result	8,309,307	8,472,113
	223,501,026	222,506,055
Non-controlling interests	307,482	231,574
	223,808,508	222,737,629
NON-CURRENT LIABILITIES		
Financial liabilities		
Liabilities to banks	64,751,483	65,096,887
	64,751,483	65,096,887
Lease liabilities	364,281,130	370,574,646
Pensions and similar commitments	36,998,711	38,198,281
Other provisions	2,333,508	2,383,578
Other payables		
Liabilities pursuant to hospital financing law	38,475,910	38,558,714
Miscellaneous payables	2,372,929	2,346,315
	40,848,839	40,905,029
	509,213,671	517,158,421
CURRENT LIABILITIES		
Trade payables	10,976,979	12,779,855
Financial liabilities		
Liabilities to banks	1,323,559	1,863,455
	1,323,559	1,863,455
Lease liabilities	26,703,015	26,592,831
Other provisions	7,556,260	10,954,702
Current income tax liabilities	8,176,258	8,023,994
Other financial liabilities		
Liabilities pursuant to Hospital Compensation Act (KHEntgG) / Federal Directive on Nursing Care Rates (BPfIV)	8,143,140	7,955,269
Miscellaneous financial liabilities	8,482,651	12,013,154
	16,625,791	19,968,423
Other payables		
Liabilities pursuant to hospital financing law	42,534,587	42,813,034
Miscellaneous payables	50,250,750	43,013,592
	92,785,337	85,826,626
Liabilities in connection with assets held for sale	0	0
	164,147,199	166,009,886
	897,169,378	905,905,936

Consolidated interim profit and loss account

in €	January – March 2025	January – March 2024
Sales	184,844,273	185,447,354
Other operating income	7,550,497	6,316,890
Total operating performance	192,394,770	191,764,244
Raw materials and consumables used		
a) Cost of raw materials and supplies	–18,310,330	–21,614,027
b) Cost of purchased services	–14,231,787	–13,955,754
	–32,542,117	–35,569,781
Staff costs		
a) Wages and salaries	–106,153,733	–103,688,142
b) Social security, pension and retirement	–19,292,647	–18,220,321
	–125,446,380	–121,908,463
Other operating expenses	–16,320,963	–18,096,995
Result before interest, taxes, depreciation and amortisation / EBITDA	18,085,310	16,189,005
Depreciation and amortisation	–12,859,509	–12,097,147
Operating result / EBIT	5,225,801	4,091,858
Financial result		
b) Interest and similar income	369,611	648,591
c) Interest and similar expenses	–5,587,288	–5,953,667
	–5,217,677	–5,305,076
Result before tax	8,124	–1,213,218
Taxes on income	–104,746	–223,407
Total consolidated result	–96,622	–1,436,625
Thereof attributable to shareholders of MEDICLIN AG	–162,806	–1,399,170
Thereof attributable to non-controlling interests	66,184	–37,455
Total consolidated result attributable to shareholders of MEDICLIN AG per share		
Undiluted in €	0.00	–0.03
Diluted in €	0.00	–0.03

Consolidated interim statement of comprehensive income

in €	January – March 2025	January – March 2024
Total consolidated result	–96,622	–1,436,625
Other comprehensive income		
Revaluation from defined benefit plans and similar obligations	1,386,992	1,112,717
Taxes on income	–219,491	–176,088
Additions to value adjustments that are not reconciled to the total consolidated result	1,167,501	936,629
Thereof attributable to shareholders of MEDICLIN AG	1,157,777	928,687
Thereof attributable to non-controlling interests	9,724	7,942
Additions to value adjustments that are reconciled to the total consolidated result	0	0
Group comprehensive income	1,070,879	–499,996
Thereof attributable to shareholders of MEDICLIN AG	994,971	–470,483
Thereof attributable to non-controlling interests	75,908	–29,513

Consolidated cash flow statement

in €	January – March 2025	January – March 2024
Total consolidated result	–96,622	–1,436,625
Result of finance activities	5,217,677	5,305,076
Result of income taxes	104,746	223,407
Operating result (EBIT)	5,225,801	4,091,858
Depreciation on fixed asset items	12,859,509	12,097,147
Result before interest, taxes, depreciation and amortisation (EBITDA)	18,085,310	16,189,005
Change in non-current provisions	–205,203	–103,427
Change in current provisions	–3,398,442	–518,515
Result from the disposal of fixed asset items	–37,392	–185,786
Result from other non-cash items	–1,668,004	–2,240,182
Change in other current assets	–3,696,300	–13,218,594
Change in other non-current liabilities	26,614	13,571
Change in other current liabilities	8,010,163	17,101,140
Payments received from interest	369,611	648,591
Income taxes paid	–399,388	–544,754
Cash flow from operating activities	17,086,969	17,141,049
Payments received from the disposal of fixed assets	81,791	226,666
From the disposal of property, plant and equipment	81,791	226,666
Payments received from investment subsidies	3,364,892	6,465,292
Cash used for investments	–10,770,029	–9,148,832
For intangible assets	–462,321	–461,822
For property, plant and equipment	–10,307,708	–8,687,010
Cash flow from investing activities	–7,323,346	–2,456,874
Repayment of lease liabilities	–6,183,332	–5,590,005
Repayment of financial liabilities	–340,712	–318,386
Interest payments for lease liabilities	–4,649,356	–4,612,374
Other interest payments	–1,122,972	–1,377,274
Cash flow from financing activities	–12,296,372	–11,898,039
Cash flow for the period	–2,532,749	2,786,136
Cash and cash equivalents at the beginning of the period	107,563,091	115,288,680
Cash and cash equivalents at the end of the period	105,030,342	118,074,816

The cash and cash equivalents at the end of the period differ from the balance sheet item “cash and cash equivalents” (difference of EUR 3,530,610) and encompass only cash in hand and current bank credit balances. This difference arose in connection with the adjustments to meet IFRS 5. The liabilities and assets held for sale of Dr. Hoefer-Janker GmbH & Co. Klinik KG and MVZ MediClin Bonn GmbH were reclassified accordingly in the balance sheet.

Statement of changes in equity

in €	Subscribed capital	Capital reserve	Revenue reserve	Consolidated balance sheet result	Shares MEDICLIN Group	Non-controlling interests	Total equity
As of 01.01.2024	47,500,000	129,391,829	35,393,431	-16,367,284	195,917,976	111,421	196,029,397
Total consolidated result	-	-	-	-1,399,170	-1,399,170	-37,455	-1,436,625
Other comprehensive income	-	-	928,687	-	928,687	7,942	936,629
Group comprehensive income	-	-	928,687	-1,399,170	-470,483	-29,513	-499,996
As of 31.03.2024	47,500,000	129,391,829	36,322,118	-17,766,454	195,447,493	81,908	195,529,401
in €	Subscribed capital	Capital reserve	Revenue reserve	Consolidated balance sheet result	Shares MEDICLIN Group	Non-controlling interests	Total equity
As of 01.01.2025	47,500,000	129,391,829	37,142,113	8,472,113	222,506,055	231,574	222,737,629
Total consolidated result	-	-	-	-162,806	-162,806	66,184	-96,622
Other comprehensive income	-	-	1,157,777	-	1,157,777	9,724	1,167,501
Group comprehensive income	-	-	1,157,777	-162,806	994,971	75,908	1,070,879
Stand 31.03.2025	47,500,000	129,391,829	38,299,890	8,309,307	223,501,026	307,482	223,808,508

Notes

General Information

The unaudited consolidated interim financial statements of MEDICLIN for the first three months of the 2025 financial year were prepared in accordance with International Accounting Standard (IAS) 34. The same accounting policies as used in the consolidated financial statements for the 2024 financial year were also applied in this interim report. The interim report should therefore be read in conjunction with the Company's published 2024 Annual Report.

The discount rate for pension provisions pursuant to IAS 19 amounted to 3.8 % on 31 March 2025 (31.12.2024: 3.5 %).

Subsequent events

Since 31 March 2025 there have been no occurrences or events of particular significance which MEDICLIN believes could have a material impact on the Group's net assets, financial position and results of operations.

MEDICLIN Aktiengesellschaft

Offenburg, 2 May 2025

The Management Board

Quarterly development in the Group

In millions of €	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024
Sales	–	–	184.8	190.6	190.2	182.6	185.4
EBITDA	–	–	18.1	32.2	35.2	20.2	16.2
EBITDA margin in %	–	–	9.8	16.9	18.5	11.1	8.7
EBIT (operating result)	–	–	5.2	19.0	22.5	7.9	4.1
EBITDA margin in %	–	–	2.8	10.0	11.8	4.3	2.2
Financial result	–	–	–5.2	–5.3	–5.4	–5.4	–5.3
Total consolidated result	–	–	–0.1	9.9	14.4	2.0	–1.4
Earnings per share in €	–	–	–	0.21	0.30	0.04	–0.03
Cash flow from operating activities	–	–	17.1	21.1	36.7	5.7	17.1
Cash flow from operating activities per share in €	–	–	0.36	0.45	0.77	0.12	0.36
Equity ratio in %	–	–	24.9	24.6	23.5	22.3	21.7
Gross capital expenditure (without right-of-use assets pursuant to IFRS 16)	–	–	12.0	14.7	11.8	9.4	10.3
Net financial debt ¹ (end of quarter)	–	–	–19.5	–18.2	–15.7	1.3	–3.6
Number of beds (inpatient)	–	–	26,064	26,725	27,403	26,664	26,703
Number of cases (end of quarter)	–	–	8,179	8,160	8,160	8,160	8,107
Occupancy rates in %	–	–	85.0	84.1	86.5	86.5	85.0
Number of full-time employees (quarterly average)	–	–	6,912	6,908	6,827	6,835	6,984

1 Adjusted net financial debt

Key data on the MEDICLIN SHARE

ISIN: DE 000659 5101; WKN: 659 510; TICKER: MED

In € per share	3M 2025	3M 2024
Earnings, undiluted / diluted	0.00	–0.03
Cash flow from operating activities	0.36	0.36
Book value ¹ as of 31.03.	4.71	4.11
Share price as of 31.03.	2.98	2.54
52-weeks high	3.10	–
52-weeks low	2.30	–
Market capitalisation as of 31.03. in millions of €	141.6	120.7
Number of shares in millions	47.5	47.5

¹ Equity less non-controlling interests

Source: Deutsche Börse AG; Xetra / as of 03.07.2023

Financial calendar

2/ February 2025

Disclosure of the preliminary figures for the 2024 financial year

28 March 2025

Annual press and analysts' conference for the 2024 financial year

2 May 2025

Publication of the interim report from 1 January 2025 to 31 March 2025

4 June 2025

Annual General Meeting

31 July 2025

Publication of the interim report from 1 January 2025 to 30 June 2025

4 November 2025

Publication of the interim report from 1 January 2025 to 30 September 2025

Adresses and imprint

MEDICLIN Aktiengesellschaft

Okenstraße 27

77652 Offenburg

Phone +49 (0) 7 81 / 4 88-0

Fax +49 (0) 7 81 / 4 88-133

E-Mail info@mediclin.de

www.mediclin.de

Investor Relations

Ender Gülcan

Phone +49 (0) 7 81 / 4 88-326

E-Mail ender.guelcan@mediclin.de

Contact for media enquiries

Corporate Communications

Dr. Janina Lossen

Phone +49 (0) 7 81 / 4 88-0

E-Mail: janina.lossen@mediclin.de

This interim report is also available in German.

This is a translation of the German Interim Report.

In case of divergence from the German version, the German version shall prevail.

